Aller au contenu principal
2024 conference-paper

Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis

1Citations signalées, ce qui n’est pas une note de qualité
6Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : de, at, jp. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

For duloxetine, a therapeutic reference range (TRR) of 30–120 ng/ml is recommended to attain an optimal antidepressant effect [1]. However, the concentration-effect relationship, which forms the basis of the TRR, lacks systematic investigation. Therefore, the current range is considered preliminary. This review investigates the optimal target concentration for duloxetine’s antidepressant effects and identifies factors moderating its blood concentrations. A systematic literature review and meta-analysis was performed. Four databases were systematically searched for relevant articles reporting duloxetine concentrations in relation to clinical effects/side effects, pharmacokinetics, or receptor occupancy. 11 studies were eligible for qualitative analyses. Evidence for a positive relationship between blood concentrations and antidepressant effect was found in three studies; a concentration-dependent occurrence for the side effect irritability/anxiety was found in one study. Across four studies ( N =223), the population-based concentration ranges were 22–67 ng/ml. A threshold of 58 ng/ml was identified for clinical response. 75 percent of responders had blood concentrations below 123 ng/ml. PET studies reported 80% serotonin transporter occupancy at blood concentrations above 10–15 ng/ml, whereas 50% norepinephrine transporter occupancy were reported above 58 ng/ml. Smoking and specific medications led to significantly lower duloxetine blood concentrations. We suggest a TRR of 20–120 ng/ml for the antidepressant effect of duloxetine. Treatment effectiveness is likely influenced by smoking and specific comedications. This warrants a special indication for therapeutic drug monitoring of duloxetine, particularly when newly prescribed. Publication History Article published online: 12 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis
Date Crossref
01/03/2024
Éditeur
Georg Thieme Verlag
Type
proceedings-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Treatment of Major Depression

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.